http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
View Older Stories View More Recent Stories
-
Exelixis (EXEL) to Present Phase 3 CELESTIAL Trial Results of Cabozantinib at 2018 ASCO-GI Symposium
-
Exelixis Announces Webcasts of Upcoming November Investor Conference Presentations
-
Exelixis Announces Phase 3 CELESTIAL Trial Results of Cabozantinib in Previously Treated Advanced Hepatocellular Carcinoma to be Presented at 2018 Gastrointestinal Cancers Symposium
-
Exelixis to Present at the Stifel 2017 Healthcare Conference on November 14th
-
Exelixis Announces Third Quarter 2017 Financial Results and Provides Corporate Update
-
Exelixis to Present at the Credit Suisse 26th Annual Healthcare Conference on November 7th
-
Exelixis to Release Third Quarter 2017 Financial Results on Wednesday, November 1, 2017
-
Exelixis (EXEL) Granted U.S. FDA Priority Review for CABOMETYX as Treatment for Previously Untreated Advanced Renal Cell Carcinom
-
Exelixis (EXEL) Reports Phase 3 CELESTIAL Trial of Cabozantinib Meets Primary Endpoint of Overall Survival
-
Exelixis Announces U.S. FDA Grants Priority Review for CABOMETYX® (Cabozantinib) as a Treatment for Previously Untreated Advanced Renal Cell Carcinoma
-
Exelixis’ Phase 3 CELESTIAL Trial of Cabozantinib Meets Primary Endpoint of Overall Survival in Patients with Advanced Hepatocellular Carcinoma
-
Exelixis (EXEL) to Receive Milestone Payment from Bristol-Myers Squibb (BMY) for RORγt Inverse Agonist Program
-
Exelixis to Receive Milestone Payment from Bristol-Myers Squibb for Submission of Clinical Trial Authorization for RORγt Inverse Agonist Program
-
Exelixis Provides Update on Collaborator Daiichi Sankyo’s Phase 3 Clinical Progress with Esaxerenone (CS-3150), Including Positive Top-Line Results and Additional Pivotal Study
-
Exelixis to Present at the Cantor Fitzgerald Healthcare Conference on September 25
-
Exelixis (EXEL) & Ipsen Reports Results from Phase 2 CABOSUN Trial of Cabozantinib Versus Sunitinib at ESMO 2017
-
Ipsen and Exelixis Announce Results from Phase 2 CABOSUN Trial of Cabozantinib versus Sunitinib in Previously Untreated Advanced Renal Cell Carcinoma at ESMO 2017
-
Exelixis and Ipsen Announce Results from Phase 2 CABOSUN Trial of Cabozantinib versus Sunitinib in Previously Untreated Advanced Renal Cell Carcinoma at ESMO 2017
-
Exelixis Debuts New Mission-Driven Corporate Branding That Supports Upcoming Milestones and Growth Strategy
-
Exelixis to Co-Host Investor/Media Briefing to Discuss Data Presented at the ESMO 2017 Congress
-
Exelixis to Present at the Morgan Stanley Global Healthcare Conference on September 13
-
Exelixis (EXEL) Submits sNDA for CABOMETYX for Treatment of Previously Untreated Advanced Kidney Cancer
-
Exelixis Submits U.S. Supplemental New Drug Application for CABOMETYX® (cabozantinib) for the Treatment of Previously Untreated Advanced Kidney Cancer
-
Exelixis Announces Second Quarter 2017 Financial Results and Provides Corporate Update
-
Exelixis-Discovered Compounds to Be Featured in 10 Presentations at ESMO 2017 Congress
-
Exelixis (EXEL), Genentech Reach Settlement in Dispute Regarding Companies' Collaboration Agreement for Cobimetinib
-
Exelixis Announces Settlement of Dispute with Genentech Regarding Companies’ Collaboration Agreement for Cobimetinib
-
Exelixis to Release Second Quarter 2017 Financial Results on Wednesday, August 2, 2017
-
Bristol-Myers Squibb (BMY) & Exelis (EXEL) Commence Phase 3 Trial of Opdivo in Combination with CABOMETYX or Opdivo & Yervoy in Combination with CABOMETYX
-
Exelixis and Bristol-Myers Squibb Initiate Phase 3 Trial of Opdivo® in Combination with CABOMETYX™ or Opdivo and Yervoy® in Combination with CABOMETYX, Versus Sunitinib in Previously Untreated Adv
-
Exelixis Repays Deerfield Notes One Year Ahead of Maturity Date, Addressing Last Major Source of Indebtedness
-
Exelixis (EXEL) Reports Independent Radiology Committee Review Confirms Results from CABOSUN, the Phase 2 Trial of Cabozantinib Versus Sunitinib
-
Exelixis Announces Independent Radiology Committee Review Confirms Results from CABOSUN, the Phase 2 Trial of Cabozantinib versus Sunitinib in Previously Untreated Advanced Renal Cell Carcinoma
-
Exelixis (EXEL) Commences Initiation of Phase 1b Trial of Cabozantinib in Combination with Atezolizumab in Patients with Locally Advanced or Metastatic Solid Tumors
-
Exelixis Announces Initiation of Phase 1b Trial of Cabozantinib in Combination with Atezolizumab in Patients with Locally Advanced or Metastatic Solid Tumors
-
Exelixis to Present at the William Blair & Co. 37th Annual Growth Stock Conference on June 13
-
Exelixis Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
-
Exelixis Announces First Quarter 2017 Financial Results and Provides Corporate Update
-
Exelixis to Present at the Deutsche Bank 42nd Annual Health Care Conference on May 3
-
Exelixis to Release First Quarter 2017 Financial Results on Monday, May 1, 2017
-
Exelixis Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
-
Exelixis Further Reduces Indebtedness by Repaying Silicon Valley Bank Term Loan
-
Exelixis to Present at the Needham & Company Healthcare Conference on April 4
-
Exelixis (EXEL) Reports Orphan Drug Designation for Cabozantinib to Treat Hepatocellular Carcinoma
-
Exelixis' Cabozantinib Granted Orphan Drug Designation for the Treatment of Hepatocellular Carcinoma
-
Exelixis Announces Webcasts of Investor Conference Presentations in March
-
Exelixis Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
-
Exelixis Announces Fourth Quarter and Full Year 2016 Financial Results and Provides Corporate Update
-
Exelixis Announces Clinical Trial Collaboration with Roche to Evaluate Cabozantinib and Atezolizumab in Locally Advanced or Metastatic Solid Tumors
-
Exelixis (EXEL), Bristol-Myers Squibb (BMY) Enter Clinical Collaboration for Late-Stage Combination Trial in First-Line Renal Cell Carcinoma
